PEGylated Recombinant Adenosine Deaminase Maintains Detoxification and Lymphocyte Counts in Patients with ADA-SCID

• Published in: Journal of clinical immunology Vol. 43; no. 5; pp. 951 - 964
• Main Authors: Dorsey, Morna J., Rubinstein, Arye, Lehman, Heather, Fausnight, Tracy, Wiley, Joseph M., Haddad, Elie
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.07.2023; Springer Nature B.V
• Subjects: Adenosine; Adenosine deaminase; Biomedical and Life Sciences; Biomedicine; Deoxyadenosine; Detoxification; Dosage; Edetic acid; Immunology; Infectious Diseases; Internal Medicine; Lymphocytes; Medical Microbiology; Metabolism; Original; Original Article; Patients; Polyethylene glycol; Severe combined immunodeficiency; Metabolic detoxification; ADA-SCID; Anti-drug antibodies; Enzyme replacement therapy; Lymphocyte counts; Elapegademase
• ISSN: 0271-9142; 1573-2592
• DOI: 10.1007/s10875-022-01426-y

  Purpose Metabolic detoxification with enzyme replacement therapy (ERT) promotes immune recovery in patients with adenosine deaminase (ADA)–deficient severe combined immunodeficiency (ADA-SCID). Elapegademase is a PEGylated recombinant bovine ADA ERT developed to replace the now-discontinued bovine-derived pegademase. This study was a 1-way crossover from pegademase to elapegademase in 7 patients with ADA-SCID to assess efficacy and safety outcomes for elapegademase. Methods After once-weekly pegademase dosage was adjusted to achieve therapeutic metabolic detoxification and trough ADA activity, patients transitioned to a bioequivalent dose of elapegademase. Maintenance of metabolic detoxification and adequate ADA activity were evaluated periodically. Results One patient withdrew after 2 doses of an early elapegademase formulation due to injection-site pain caused by EDTA. The 6 remaining patients completed 71−216 weeks of elapegademase therapy with a formulation that did not contain EDTA. In these patients, elapegademase improved ADA activity compared with pegademase and maintained metabolic detoxification. Total lymphocyte counts increased for all completer patients from between 1.2- and 2.1-fold at the end of study compared with baseline. Elapegademase had a comparable safety profile to pegademase; no patient developed a severe infectious complication. Three patients had transient, non-neutralizing antibodies to pegademase, elapegademase, and/or polyethylene glycol ≤ 47 weeks of treatment without effect on trough plasma ADA activity or trough erythrocyte deoxyadenosine nucleotide levels. Conclusion Elapegademase was safe, well tolerated, achieved stable trough plasma ADA activity with weekly dosing, was effective in maintaining metabolic detoxification, and was associated with maintenance or improvements in lymphocyte counts compared with pegademase therapy in patients with ADA-SCID.